Press Releases | Intrexon https://investors.dna.com/ Intrexon Business Update and Conference Call https://investors.dna.com/2018-08-09-Intrexon-Business-Update-and-Conference-Call Thu, 09 Aug 2018 16:57:00 -0400 https://investors.dna.com/2018-08-09-Intrexon-Business-Update-and-Conference-Call Intrexon to Present at the Jefferies 2018 Global Industrials Conference https://investors.dna.com/2018-08-03-Intrexon-to-Present-at-the-Jefferies-2018-Global-Industrials-Conference Fri, 03 Aug 2018 07:30:00 -0400 https://investors.dna.com/2018-08-03-Intrexon-to-Present-at-the-Jefferies-2018-Global-Industrials-Conference Intrexon to Announce Second Quarter and First Half 2018 Financial Results on August 9th https://investors.dna.com/2018-08-02-Intrexon-to-Announce-Second-Quarter-and-First-Half-2018-Financial-Results-on-August-9th Thu, 02 Aug 2018 07:30:00 -0400 https://investors.dna.com/2018-08-02-Intrexon-to-Announce-Second-Quarter-and-First-Half-2018-Financial-Results-on-August-9th Intrexon Announces Pricing of Offerings of Convertible Senior Notes and Common Stock https://investors.dna.com/2018-06-29-Intrexon-Announces-Pricing-of-Offerings-of-Convertible-Senior-Notes-and-Common-Stock Fri, 29 Jun 2018 06:00:00 -0400 https://investors.dna.com/2018-06-29-Intrexon-Announces-Pricing-of-Offerings-of-Convertible-Senior-Notes-and-Common-Stock Intrexon Announces Proposed Offerings of Convertible Senior Notes and Common Stock https://investors.dna.com/2018-06-27-Intrexon-Announces-Proposed-Offerings-of-Convertible-Senior-Notes-and-Common-Stock Wed, 27 Jun 2018 16:47:00 -0400 https://investors.dna.com/2018-06-27-Intrexon-Announces-Proposed-Offerings-of-Convertible-Senior-Notes-and-Common-Stock Oxitec to Apply New Generation of Self-Limiting Mosquito Technology to Malaria-Spreading Mosquitoes https://investors.dna.com/Oxitec-to-Apply-New-Generation-of-Self-Limiting-Mosquito-Technology-to-Malaria-Spreading-Mosquitoes – Oxitec’s first step into global malaria vector control efforts in partnership with the Bill & Melinda Gates Foundation – Agreement covers the first strain of Oxitec’s genetically-engineered mosquitoes specifically designed to combat malaria vector – Sat, 09 Jun 2018 09:35:00 -0400 https://investors.dna.com/Oxitec-to-Apply-New-Generation-of-Self-Limiting-Mosquito-Technology-to-Malaria-Spreading-Mosquitoes Isolation and Recombinant Expression of Key Enzyme for Opioid Production https://investors.dna.com/2018-05-29-Isolation-and-Recombinant-Expression-of-Key-Enzyme-for-Opioid-Production Long Postulated Enzyme Thebaine Synthase Potentiates Efficient Biosynthesis of Opioids by Increasing Thebaine Titers >20-fold in Engineered Yeast Strains Tue, 29 May 2018 08:00:00 -0400 https://investors.dna.com/2018-05-29-Isolation-and-Recombinant-Expression-of-Key-Enzyme-for-Opioid-Production Precigen Announces First Patient Dosed in Phase 1 Clinical Study of INXN-4001 https://investors.dna.com/2018-05-21-Precigen-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Study-of-INXN-4001 Milestone represents the first ever triple effector gene therapy for heart failure Mon, 21 May 2018 08:00:00 -0400 https://investors.dna.com/2018-05-21-Precigen-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Study-of-INXN-4001 Intrexon to Participate in the Bank of America Merrill Lynch 2018 Healthcare Conference https://investors.dna.com/2018-05-14-Intrexon-to-Participate-in-the-Bank-of-America-Merrill-Lynch-2018-Healthcare-Conference Mon, 14 May 2018 08:00:00 -0400 https://investors.dna.com/2018-05-14-Intrexon-to-Participate-in-the-Bank-of-America-Merrill-Lynch-2018-Healthcare-Conference Intrexon Announces First Quarter 2018 Financial Results https://investors.dna.com/2018-05-10-Intrexon-Announces-First-Quarter-2018-Financial-Results - Quarterly GAAP revenues of $43.8 million and net loss attributable to Intrexon of $42.0 million including non-cash charges of $26.3 million - Thu, 10 May 2018 16:05:00 -0400 https://investors.dna.com/2018-05-10-Intrexon-Announces-First-Quarter-2018-Financial-Results Intrexon to Announce First Quarter 2018 Financial Results on May 10th https://investors.dna.com/2018-05-03-Intrexon-to-Announce-First-Quarter-2018-Financial-Results-on-May-10th Thu, 03 May 2018 08:00:00 -0400 https://investors.dna.com/2018-05-03-Intrexon-to-Announce-First-Quarter-2018-Financial-Results-on-May-10th Exemplar Genetics Rare Neurological Disease Model Cleared by FDA for Commercial Research Use https://investors.dna.com/2018-04-16-Exemplar-Genetics-Rare-Neurological-Disease-Model-Cleared-by-FDA-for-Commercial-Research-Use Mon, 16 Apr 2018 07:00:00 -0400 https://investors.dna.com/2018-04-16-Exemplar-Genetics-Rare-Neurological-Disease-Model-Cleared-by-FDA-for-Commercial-Research-Use ActoBio Therapeutics Greenlighted by FDA to Commence a Phase Ib/IIa Trial with AG019 for the Treatment of Early Onset Type 1 Diabetes https://investors.dna.com/2018-03-29-ActoBio-Therapeutics-Greenlighted-by-FDA-to-Commence-a-Phase-Ib-IIa-Trial-with-AG019-for-the-Treatment-of-Early-Onset-Type-1-Diabetes A unique combination approach to oral tolerance made possible by L. lactis therapeutic protein delivery Thu, 29 Mar 2018 09:26:00 -0400 https://investors.dna.com/2018-03-29-ActoBio-Therapeutics-Greenlighted-by-FDA-to-Commence-a-Phase-Ib-IIa-Trial-with-AG019-for-the-Treatment-of-Early-Onset-Type-1-Diabetes Intrexon Announces Fourth Quarter and Full Year 2017 Financial Results https://investors.dna.com/2018-03-01-Intrexon-Announces-Fourth-Quarter-and-Full-Year-2017-Financial-Results - Quarterly GAAP revenues of $77.0 million and net loss attributable to Intrexon of $27.3 million including non-cash charges of $41.5 million - Thu, 01 Mar 2018 16:05:00 -0500 https://investors.dna.com/2018-03-01-Intrexon-Announces-Fourth-Quarter-and-Full-Year-2017-Financial-Results Intrexon to Announce Fourth Quarter and Full Year 2017 Financial Results on March 1st https://investors.dna.com/2018-02-22-Intrexon-to-Announce-Fourth-Quarter-and-Full-Year-2017-Financial-Results-on-March-1st Thu, 22 Feb 2018 08:00:00 -0500 https://investors.dna.com/2018-02-22-Intrexon-to-Announce-Fourth-Quarter-and-Full-Year-2017-Financial-Results-on-March-1st Intrexon Announces Closing of Public Offering of Common Stock and Exercise of Option by Underwriters https://investors.dna.com/2018-01-19-Intrexon-Announces-Closing-of-Public-Offering-of-Common-Stock-and-Exercise-of-Option-by-Underwriters Fri, 19 Jan 2018 10:41:00 -0500 https://investors.dna.com/2018-01-19-Intrexon-Announces-Closing-of-Public-Offering-of-Common-Stock-and-Exercise-of-Option-by-Underwriters Intrexon Prices Public Offering of Common Stock https://investors.dna.com/2018-01-17-Intrexon-Prices-Public-Offering-of-Common-Stock Wed, 17 Jan 2018 09:16:00 -0500 https://investors.dna.com/2018-01-17-Intrexon-Prices-Public-Offering-of-Common-Stock Intrexon Announces Proposed Public Offering of Common Stock https://investors.dna.com/2018-01-16-Intrexon-Announces-Proposed-Public-Offering-of-Common-Stock Tue, 16 Jan 2018 16:15:00 -0500 https://investors.dna.com/2018-01-16-Intrexon-Announces-Proposed-Public-Offering-of-Common-Stock Intrexon's ActoBio Therapeutics to Present at Biotech Showcase 2018 on January 8 https://investors.dna.com/2018-01-04-Intrexons-ActoBio-Therapeutics-to-Present-at-Biotech-Showcase-2018-on-January-8 Thu, 04 Jan 2018 08:35:00 -0500 https://investors.dna.com/2018-01-04-Intrexons-ActoBio-Therapeutics-to-Present-at-Biotech-Showcase-2018-on-January-8 Intrexon to Present at the 36th Annual J.P. Morgan Healthcare Conference https://investors.dna.com/2018-01-04-Intrexon-to-Present-at-the-36th-Annual-J-P-Morgan-Healthcare-Conference Thu, 04 Jan 2018 08:30:00 -0500 https://investors.dna.com/2018-01-04-Intrexon-to-Present-at-the-36th-Annual-J-P-Morgan-Healthcare-Conference Intrexon Corporation Annual CEO Letter https://investors.dna.com/2018-01-02-Intrexon-Corporation-Annual-CEO-Letter Tue, 02 Jan 2018 08:00:00 -0500 https://investors.dna.com/2018-01-02-Intrexon-Corporation-Annual-CEO-Letter Intrexon Announces Key Management Appointments https://investors.dna.com/2017-11-27-Intrexon-Announces-Key-Management-Appointments Mon, 27 Nov 2017 08:00:00 -0500 https://investors.dna.com/2017-11-27-Intrexon-Announces-Key-Management-Appointments Intrexon to Present at the Stifel 2017 Healthcare Conference https://investors.dna.com/2017-11-10-Intrexon-to-Present-at-the-Stifel-2017-Healthcare-Conference Fri, 10 Nov 2017 08:00:00 -0500 https://investors.dna.com/2017-11-10-Intrexon-to-Present-at-the-Stifel-2017-Healthcare-Conference Intrexon Announces Third Quarter 2017 Financial Results https://investors.dna.com/2017-11-09-Intrexon-Announces-Third-Quarter-2017-Financial-Results - Quarterly GAAP revenues of $46.0 million and net loss attributable to Intrexon of $39.7 million including non-cash charges of $24.0 million - Thu, 09 Nov 2017 16:05:00 -0500 https://investors.dna.com/2017-11-09-Intrexon-Announces-Third-Quarter-2017-Financial-Results Intrexon to Announce Third Quarter 2017 Financial Results on November 9th https://investors.dna.com/2017-11-01-Intrexon-to-Announce-Third-Quarter-2017-Financial-Results-on-November-9th Wed, 01 Nov 2017 08:00:00 -0400 https://investors.dna.com/2017-11-01-Intrexon-to-Announce-Third-Quarter-2017-Financial-Results-on-November-9th